Form 144 ANI PHARMACEUTICALS INC Filed by: Thoma Jeanne

Fri, 11 Sep 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260911/27053268.html

Leerink Starts ANI Pharmaceuticals (ANIP) at Outperform

Wed, 09 Sep 2026 06:49:09 -0400

Leerink analyst Daniel Clark initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Outperform rating and a price target of $104.00.

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $70.23 yesterday.

ANI Pharmaceuticals to Present at September Investor Conferences

Thu, 03 Sep 2026 06:55:00 -0400

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in fireside chats at the following upcoming investor conferences:

ANI Pharmaceuticals to Present at September Investor Conferences

Thu, 03 Sep 2026 06:55:00 -0400








	Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O Thu, 27 Aug 2026 16:22:00 -0400 si-local-file:///var/storage/secattach/20260827/26990337.html Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O Thu, 27 Aug 2026 16:22:00 -0400 si-local-file:///var/storage/secattach/20260827/26990337.html Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O Thu, 27 Aug 2026 16:20:00 -0400 si-local-file:///var/storage/secattach/20260827/26990306.html Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O Thu, 27 Aug 2026 16:20:00 -0400 si-local-file:///var/storage/secattach/20260827/26990306.html Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil Wed, 26 Aug 2026 18:15:00 -0400 si-local-file:///var/storage/secattach/20260826/26983095.html Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil Wed, 26 Aug 2026 18:15:00 -0400 si-local-file:///var/storage/secattach/20260826/26983095.html Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil Tue, 25 Aug 2026 16:42:00 -0400 si-local-file:///var/storage/secattach/20260825/26975314.html Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil Tue, 25 Aug 2026 16:42:00 -0400 si-local-file:///var/storage/secattach/20260825/26975314.html Form 8-K ANI PHARMACEUTICALS INC For: Aug 19 Mon, 24 Aug 2026 07:01:00 -0400 si-local-file:///var/storage/secattach/20260824/26964083.html Form 8-K ANI PHARMACEUTICALS INC For: Aug 19 Mon, 24 Aug 2026 07:01:00 -0400 si-local-file:///var/storage/secattach/20260824/26964083.html ANI Pharmaceuticals adds Henry Gosebruch to its board Mon, 24 Aug 2026 06:55:14 -0400 ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) appointed Henry Gosebruch to its board of directors, effective August 19, 2026, according to a company statement. Gosebruch currently serves as chief executive officer of Lakefront Biotherapeutics NV, formerly known as Galapagos NV, a position he has held since May 2025. Before that, he was president and chief executive officer of Neumora Therapeutics, Inc. from July 2023 to February 2025. From 2015 to 2023, Gosebruch was executive vice president and chief strategy officer at AbbVie, where he oversaw corporate strategy, business development, and mergers and acquisitions. During that period, the group completed more than 100 transactions and ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors Mon, 24 Aug 2026 06:55:00 -0400 – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors Mon, 24 Aug 2026 06:55:00 -0400 – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors Mon, 24 Aug 2026 06:55:00 -0400 – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors Mon, 24 Aug 2026 06:55:00 -0400 – Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector. “We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith Thu, 13 Aug 2026 16:33:00 -0400 si-local-file:///var/storage/secattach/20260813/26921937.html Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith Thu, 13 Aug 2026 16:33:00 -0400 si-local-file:///var/storage/secattach/20260813/26921937.html Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori Tue, 11 Aug 2026 20:57:00 -0400 si-local-file:///var/storage/secattach/20260811/26907607.html Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori Tue, 11 Aug 2026 20:57:00 -0400 si-local-file:///var/storage/secattach/20260811/26907607.html ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim Mon, 10 Aug 2026 07:39:43 -0400 (Updated - August 10, 2026 7:39 AM EDT) Guggenheim analyst Vamil Divan lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $119.00 (from $124.00) while maintaining a Buy rating. The analyst commented: "We are updating our ANIP company model following the company's 2Q 2026 earnings and our follow-up conversation with management. The company reported overall 2Q 2026 results that were ahead of expectations, with the upside driven primarily by Generics and Brand Royalties and Other Revenues. However, while FY 2026 guidance for total net revenues, EBITDA, and EPS were maintained, the company's 2Q 2026 Cortrophin sales were at the very low ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim Mon, 10 Aug 2026 07:39:43 -0400 (Updated - August 10, 2026 7:39 AM EDT) Guggenheim analyst Vamil Divan lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $119.00 (from $124.00) while maintaining a Buy rating. The analyst commented: "We are updating our ANIP company model following the company's 2Q 2026 earnings and our follow-up conversation with management. The company reported overall 2Q 2026 results that were ahead of expectations, with the upside driven primarily by Generics and Brand Royalties and Other Revenues. However, while FY 2026 guidance for total net revenues, EBITDA, and EPS were maintained, the company's 2Q 2026 Cortrophin sales were at the very low

StreetInsider.com News Articles

Form 144 ANI PHARMACEUTICALS INC Filed by: Thoma Jeanne

Leerink Starts ANI Pharmaceuticals (ANIP) at Outperform

ANI Pharmaceuticals to Present at September Investor Conferences

ANI Pharmaceuticals to Present at September Investor Conferences

Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Form 4 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Form 3 ANI PHARMACEUTICALS INC For: Aug 19 Filed by: Gosebruch Henry O

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Form 4 ANI PHARMACEUTICALS INC For: Aug 25 Filed by: Lalwani Nikhil

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Form 144 ANI PHARMACEUTICALS INC Filed by: Lalwani Nikhil

Form 8-K ANI PHARMACEUTICALS INC For: Aug 19

Form 8-K ANI PHARMACEUTICALS INC For: Aug 19

ANI Pharmaceuticals adds Henry Gosebruch to its board

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith

Form 4 ANI PHARMACEUTICALS INC For: Aug 13 Filed by: Cook Meredith

Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori

Form 4 ANI PHARMACEUTICALS INC For: Aug 10 Filed by: Gutwerg Ori

ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim

ANI Pharmaceuticals (ANIP) PT Lowered to $119 at Guggenheim